Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $58.56 --0%
EPS Growth %: +10.3%
Financial Fact:
Cost of products sold: 1.31B
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: +10.3%
Financial Fact:
Cost of products sold: 1.31B
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.94, $0.09 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5.97 billion versus the consensus estimate of $5.99 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2019 EPS of $4.10-$4.20, versus the consensus of $4.14.
- Worldwide revenues increasing in the mid-single digits.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
- Softbank stock target raised at Citi on profit growth
- Chip stocks hit record 19.7% of S&P 500, quadrupling since 2020
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
